Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Nardilysin controls intestinal tumorigenesis through HDAC1/p53–dependent transcriptional regulation
Keitaro Kanda, Jiro Sakamoto, Yoshihide Matsumoto, Kozo Ikuta, Norihiro Goto, Yusuke Morita, Mikiko Ohno, Kiyoto Nishi, Koji Eto, Yuto Kimura, Yuki Nakanishi, Kanako Ikegami, Takaaki Yoshikawa, Akihisa Fukuda, Kenji Kawada, Yoshiharu Sakai, Akihiro Ito, Minoru Yoshida, Takeshi Kimura, Tsutomu Chiba, Eiichiro Nishi, Hiroshi Seno
Keitaro Kanda, Jiro Sakamoto, Yoshihide Matsumoto, Kozo Ikuta, Norihiro Goto, Yusuke Morita, Mikiko Ohno, Kiyoto Nishi, Koji Eto, Yuto Kimura, Yuki Nakanishi, Kanako Ikegami, Takaaki Yoshikawa, Akihisa Fukuda, Kenji Kawada, Yoshiharu Sakai, Akihiro Ito, Minoru Yoshida, Takeshi Kimura, Tsutomu Chiba, Eiichiro Nishi, Hiroshi Seno
View: Text | PDF
Research Article Oncology

Nardilysin controls intestinal tumorigenesis through HDAC1/p53–dependent transcriptional regulation

  • Text
  • PDF
Abstract

Colon cancer is a complex disease affected by a combination of genetic and epigenetic factors. Here we demonstrate that nardilysin (N-arginine dibasic convertase; NRDC), a metalloendopeptidase of the M16 family, regulates intestinal tumorigenesis via its nuclear functions. NRDC is highly expressed in human colorectal cancers. Deletion of the Nrdc gene in ApcMin mice crucially suppressed intestinal tumor development. In ApcMin mice, epithelial cell–specific deletion of Nrdc recapitulated the tumor suppression observed in Nrdc-null mice. Moreover, epithelial cell–specific overexpression of Nrdc significantly enhanced tumor formation in ApcMin mice. Notably, epithelial NRDC controlled cell apoptosis in a gene dosage–dependent manner. In human colon cancer cells, nuclear NRDC directly associated with HDAC1, and controlled both acetylation and stabilization of p53, with alterations of p53 target apoptotic factors. These findings demonstrate that NRDC is critically involved in intestinal tumorigenesis through its epigenetic regulatory function, and targeting NRDC may lead to a novel prevention or therapeutic strategy against colon cancer.

Authors

Keitaro Kanda, Jiro Sakamoto, Yoshihide Matsumoto, Kozo Ikuta, Norihiro Goto, Yusuke Morita, Mikiko Ohno, Kiyoto Nishi, Koji Eto, Yuto Kimura, Yuki Nakanishi, Kanako Ikegami, Takaaki Yoshikawa, Akihisa Fukuda, Kenji Kawada, Yoshiharu Sakai, Akihiro Ito, Minoru Yoshida, Takeshi Kimura, Tsutomu Chiba, Eiichiro Nishi, Hiroshi Seno

×

Figure 6

NRDC interacts with HDAC1.

Options: View larger image (or click on image) Download as PowerPoint
NRDC interacts with HDAC1.
(A) HCT116 cells, in which NRDC was knocked d...
(A) HCT116 cells, in which NRDC was knocked down (control, miR-1, miR-2), were treated with or without 5-fluorouracil (5-FU, 5 μM) and oxaliplatin (L-OHP, 1 μM) in combination either with nicotinic acid (NA, 500 μM) or tricostatin A (TSA, 250 nM) for 48 hours and harvested for Western blotting. TSA cancelled the enhancement of p53 acetylation and increased apoptotic proteins. (B) HCT116 cells, in which NRDC and HDAC1 were concomitantly knocked down, were treated with or without 5-FU (5 μM) and L-OHP (1 μM) for 48 hours and harvested for Western blotting with the indicated antibodies. (C) Representative images from an in situ proximity ligation assay to show the interaction between NRDC and HDAC1 in HCT116 cells. Nuclei were defined by DAPI staining. (D) The 293T cells were transfected with the indicated expression vectors, followed by immunoprecipitation (IP) of the cotransfected cell lysates with control IgG, anti-FLAG, or anti-V5 antibodies. Western blotting indicated that NRDC directly associates with HDAC1. IB indicates antibodies used for immunoblotting.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts